Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Shionogi Licenses NF-κB Decoy Oligo from AnGes MG
January 10, 2011
- Pharmarise to Increase Sales in Home Healthcare Business
January 10, 2011
- National Medical Expenditure Up 2% to ¥34,808.4 Bil.
January 10, 2011
- BMS Licenses Festinavir from Oncolys
January 10, 2011
- Signatures from 2.7 Mil. People Presented Demanding Expansion of Vaccination Programs
January 10, 2011
- Bristol-Myers, Otsuka Starts Copromoting Sprycel in Japan
January 10, 2011
- JRIA Hosts Seminar for Promoting Benefits of RI Treatment
January 10, 2011
- Eisai to Markets Analgesic Poultice in China
January 10, 2011
- FDA Warns Yuki Gosei Kogyo against CGMP Violations
January 10, 2011
- Takeda Settles with 11 US Generic Firms Regarding Generics of Actos
January 10, 2011
- Memantine's Package Insert to Include No Precaution on Coadministration with Aricept
January 10, 2011
- Barclays Revises MTPC's Business Forecasts Upward
January 10, 2011
- RaQualia Ties Up with Eli Lilly for Pain Treatments
January 10, 2011
- Need to Reduce the Number of Generics Pointed Out at Chuikyo
January 10, 2011
- METI's Life Innovation-Related Budgets Down ¥230 Mil. to ¥8,280 Mil.
January 10, 2011
- Korosho to Support First-in-Human Trials in Earnest
January 10, 2011
- Research Spending down 7.9% to ¥1,193.7 Bil. for Pharma Industry in FY2009
January 10, 2011
- Hospira Japan to Begin Development of Biosimilars in Japan
January 10, 2011
- Korosho Obliged to Make a Sensitive Decision on Actos Generics
January 10, 2011
- NIBIO Identifies Structure of TNF-TNFR2 Complex
January 10, 2011
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…